Table 2 |.

Novel risk loci for EF and cardiomyopathy identified in childhood cancer survivors exposed to cardiotoxic therapies

Chr	SNP	Position	EA/OA	Survivor cohorts	EF				CTCAE grade 2–4 cardiomyopathy			CTCAE grade 3–4 cardiomyopathy
					EAF	BETA	SE	P	EAFsurvivor cases/EAFsurvivor controls	OR (95% CI)	P	EAFsurvivor cases/EAFsurvivor controls	OR (95% CI)	P
1	rs6689879	113559097	C/T	African discovery	0.17	−0.042	0.007	2.8×10−8	0.26/0.15	3.71 (1.87–7.37)	1.8×10−4	0.35/0.15	5.43 (2.20–13.43)	2.5×10−4
				European Replication	0.30	−0.004	0.002	0.042	0.34/0.30	1.24 (0.98–1.56)	0.071	0.35/0.30	1.31 (0.88–1.94)	0.19
15	rs9788776	87090779	G/A	African discovery	0.08	−0.059	0.01	3.5×10−8	0.21/0.06	5.24 (2.30–11.92)	7.9×10−5	0.18/0.06	4.51 (1.52–13.37)	6.6×10−3
				European Replication	Monomorphic

Chr, chromosome; Genomic position is based on GRCh38 genome build; EA, effect allele; OA, other allele; EAF, effect allele frequency; BETA, effect size; SE, standard error; OR, odds ratio; CI, confidence interval; Cardiotoxic therapies (either anthracycline chemotherapy and/or heart radiotherapy); Cases are survivors affected with cardiomyopathy; Controls are free from cardiomyopathy; Discovery cohort included 246 survivors of African ancestry exposed to cardiotoxic therapies, and the replication cohort included 1645 survivors of European ancestry exposed to cardiotoxic therapies